Dermatitis

Adults who were taking dupilumab for their atopic dermatitis also experienced significant improvements in their mild asthma, primarily in the first 16 weeks, according to a study published in Clinical and Translational Allergy.

MIAMI BEACH, Florida — In two-real world studies, Dupixent treatment led to similar rapid and sustained improvements in patients with atopic dermatitis, according to a poster presentation at South Beach Symposium.

Combination lebrikizumab and topical corticosteroids outperformed topical corticosteroids alone in the treatment of atopic dermatitis in adolescents and adults, according to a phase 3 study.

The European Medicines Agency has recommended extending Dupixent approval to treat severe atopic dermatitis in children aged 6 months to 5 years in the European Union, Regeneron Pharmaceuticals and Sanofi announced in a press release.

Previously administered orally, brepocitinib proved to be effective and well tolerated as a topical formation in patients with mild to moderate atopic dermatitis, according to a phase 2b study.

The FDA’s approval of Rinvoq, a selective Janus kinase (JAK) inhibitor, was Healio’s most read dermatitis story in 2022, with multiple articles about Cibinqo and roflumilast following close behind.

Patients with moderate to severe atopic dermatitis showed promising results during and up to 20 weeks after treatment in a clinical trial evaluating rocatinlimab, according to a study.

Ruxolitinib cream demonstrated efficacy and tolerability in patients with atopic dermatitis during 44 weeks of as-needed treatment, according to two phase 3 trials.

Roflumilast cream was an effective and safe treatment for mild to moderate atopic dermatitis in adults and children aged 6 years and older, Arcutis Biotherapeutics announced in a press release.

Serum dupilumab levels showed no correlation to treatment response or adverse events in patients with atopic dermatitis during the first year of treatment, according to a study.